Navigation Links
Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Date:9/5/2011

e and need to patients of the other gene therapy programs."

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results coul
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Molecular sleuths track evolution through the ribosome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 - Elsevier, a world-leading provider of ... announced the publication of a recent study in ... human blastocysts showing that those with an abnormal chromosomal ... they have developed to blastocysts, thereby classifying the risk ... study the same group has undertaken a retrospective study, ...
(Date:5/17/2013)... 2013  Cellular Biomedicine Group (OTCQB: CBMG) today ... the total projected enrollment required for its Phase ... efficacy of the medical technology haMPC (Human Adipose-derived ... To date the trial has had no Severe ... I open label clinical research trial for KOA, ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( says skin ... known to react more aggressively when hormones change, and acne ... other acne causing factors like P.acnes bacteria and excess dirt ... unsightly acne scars. Adult acne treatment, Probiotic Action shares new ... to reduce and prevent acne scarring. , In order to ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 IAC Industries wants ... a start up laboratory needing to set up and furnish ... to a larger facility within a year’s time. How does ... that the laboratory is temporary? What is efficient and cost-effective? ... modular workstations from IAC Industries. The planners at DisperSol determined ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... YORK, Feb. 24, 2011 Reportlinker.com announces that ... its catalogue: Propylene Oxide: 2010 ... http://www.reportlinker.com/p0152026/Propylene-Oxide-2010-World-Market-Outlook-And-Forecast.html The report analyzes ... North America and Latin America. It provides the ...
... 24, 2011 Reportlinker.com announces that a new ... Global Marine Biotechnology Industry ... This report analyzes the Global markets for ... product segments- Marine Biomaterials, Marine Bioactive Substances, and ...
... Feb. 24, 2011 Palatin Technologies, Inc. (NYSE Amex: ... public offering of 23,000,000 units, consisting of 23,000,000 shares of ... of its common stock and Series B Warrants to purchase ... the public of $1.00 per unit. Palatin expects that the ...
Cached Biology Technology:Reportlinker Adds Propylene Oxide: 2010 World Market Outlook and Forecast 2Reportlinker Adds Global Marine Biotechnology Industry 2Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 2Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 3
(Date:5/16/2013)... NEW YORK , May 16, 2013 ... market research report is available in its ... Market Forecast & Opportunities, 2018 ... data protection and old security practises such ... driven the growth of biometric technologies in ...
(Date:5/15/2013)... touting its benefit in moderating gout risk, new research ... not reduce uric acid (urate) levels to a clinically ... supplementation, alone or in combination with allopurinol, appears to ... in gout patients according to the results published in ... & Rheumatism . , Gout is an inflammatory ...
(Date:5/15/2013)... PHILADELPHIA In the largest clinical trial to date ... BRCA 1/2 carriers with diseases other than breast and ... be effective against advanced pancreatic and prostate cancers. Results ... School of Medicine at the University of Pennsylvania and ... presented during the American Society of Clinical Oncology,s annual ...
Breaking Biology News(10 mins):Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7Vitamin C does not lower uric acid levels in gout patients 2PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... Berkeley Girls in homes without a biological father ... according to a new study led by researchers at the ... The findings, to be published Sept. 17 in the ... a biologically related father in the home predicted earlier breast ...
... More than 100 marine scientists, policy makers and members ... network of observatories monitoring Europe,s seas, at the ... Observatories,. This will give reliable, long-term data to underpin ... fisheries, aquaculture, energy, shipping, as well as tourism and ...
... CORVALLIS, Ore. Researchers at Oregon State University have ... a type of nanostructure that has gained significant ... surface area in microreactors. The findings, announced in ... door to important new nanotech applications in production of ...
Cached Biology News:Father absence linked to earlier puberty among certain girls 2Father absence linked to earlier puberty among certain girls 3Father absence linked to earlier puberty among certain girls 4Watch your seas: Marine scientists call for European marine observatory network 2'Nanosprings' offer improved performance in biomedicine, electronics 2
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... supernates and serum. Each kit contains sufficient ... 96-well plates, provided that the following conditions ...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Blimp-1 (H-150)...
SCP-1 (P-17)...
Biology Products: